Table S1. Impact of clinical and pathological features on OS, TTR and early recurrence in validation cohort (n=108).
| Variables | OS (n=108) | TTR (n=108) | Early recurrence (n=108) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | ||||||||||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | ||||||
| Clinical features | |||||||||||||||||
| Gender (male vs. female) | 1.266 (0.881–1.819) | 0.202 | NA | 1.106 (0.773–1.583) | 0.581 | NA | 1.448 (0.857–2.448) | 0.166 | NA | ||||||||
| Age, median (range), years | 1.026 (0.726–1.448) | 0.886 | NA | 0.994 (0.703–1.406) | 0.973 | NA | 0.667 (0.406–1.907) | 0.111 | NA | ||||||||
| HBV infection (negative vs. positive) | 0.751 (0.528–1.068) | 0.111 | NA | 0.755 (0.528–1.078) | 0.122 | NA | 1.018 (0.612–1.693) | 0.945 | NA | ||||||||
| AFP (ng/mL) (<20 vs. ≥20) | 0.628 (0.347–1.138) | 0.125 | NA | 0.784 (0.450–1.366) | 0.390 | NA | 0.780 (0.371–1.639) | 0.513 | NA | ||||||||
| CA-199 (U/mL) (<37 vs. ≥37) | 1.284 (0.910–1.813) | 0.155 | NA | 1.232 (0.871–1.744) | 0.238 | NA | 1.825 (1.112–2.996) | 0.017* | 1.768 (1.035–3.020) | 0.037* | |||||||
| Lymphonodus metastasis (absent vs. present) | 3.700 (2.468–5.547) | <0.001* | 5.075 (1.383–18.616) | 0.014* | 3.041 (2.012–4.598) | <0.001* | 3.983 (1.208–13.234) | 0.023 | 3.890 (2.211–6.843) | <0.001* | 2.893 (0.792–10.569) | 0.108 | |||||
| TNM stage (I vs. II+III) | 2.819 (1.929–4.120) | <0.001* | 0.629 (0.185–2.136) | 0.457 | 2.343 (1.587–3.461) | <0.001* | 0.763 (0.262–2.226) | 0.621 | 2.903 (1.710–4.926) | <0.001* | 0.899 (0.266–3.040) | 0.864 | |||||
| Child-Pugh stage (A vs. B) | 0.694 (0.221–2.183) | 0.532 | NA | 0.869 (0.321–2.354) | 0.782 | NA | 5.138 (1.207–21.864) | 0.027* | 1.394 (0.301–6.445) | 0.671 | |||||||
| General macroscopic | |||||||||||||||||
| Tumor number (single vs. multiple) | 1.846 (1.266–2.692) | 0.001* | 0.950 (0.541–1.669) | 0.858 | 2.020 (1.385–2.946) | <0.001* | 1.750 (1.002–3.056) | 0.049* | 1.986 (1.178–3.346) | 0.01* | 1.760 (0.978–3.167) | 0.059 | |||||
| Tumor size (≤5 vs. >5) | 1.735 (1.218–2.472) | 0.002* | 1.712 (1.029–2.847) | 0.039* | 1.340 (0.944–1.902) | 0.101 | NA | 1.542 (0.937–2.536) | 0.088 | NA | |||||||
| Macrovascular invasion (absent vs. present) | 1.212 (0.744–1.975) | 0.440 | NA | 1.310 (0.813–2.112) | 0.268 | NA | 0.817 (0.372–1.793) | 0.614 | NA | ||||||||
| General microscopic | |||||||||||||||||
| Liver cirrhosis (absent vs. present) | 1.102 (0.750–1.620) | 0.620 | NA | 1.073 (0.725–1.590) | 0.724 | NA | 1.152 (0.682–1.945) | 0.597 | NA | ||||||||
| Tumor encapsulation (complete vs. none) | 1.230 (0.727–2.079) | 0.441 | NA | 1.274 (0.743–2.184) | 0.379 | NA | 0.817 (0.443–1.505) | 0.516 | NA | ||||||||
| Follow-up | |||||||||||||||||
| Recurrence (≤2 vs. >2 years) | 1.939 (1.380–2.723) | <0.001* | 1.407 (0.914–2.166) | 0.121 | 2.793 (2.044–3.816) | <0.001* | 2.513 (1.713–3.686) | <0.001* | NA | NA | |||||||
| VETC (absent vs. present) | 2.064 (1.428–2.982) | <0.001* | 1.899 (1.318–2.734) | 0.001* | 2.368 (1.339–4.188) | 0.003* | |||||||||||
| PD-L1 (low vs. high) | 2.096 (1.466–2.997) | <0.001* | 1.750 (1.229–2.493) | 0.002* | 1.591 (0.966–2.618) | 0.068 | |||||||||||
| Intratumoral VETC/PD-L1 index | <0.001* | 0.023* | <0.001* | 0.111 | 0.003* | 0.002 | |||||||||||
| I | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | |||||||||||
| II | 0.201 (0.109–0.372) | 0.265 (0.101–0.700) | 0.261 (0.145–0.469) | 0.431 (0.163–1.142) | 0.233 (0.095–0.570) | 0.261 (0.106–0.644) | |||||||||||
| III | 0.755 (0.496–1.149) | 0.924 (0.556–1.595) | 0.782 (0.508–1.204) | 1.206 (0.716–2.031) | 1.058 (0.627–1.786) | 1.370 (0.775–2.420) | |||||||||||
*, P value showed statistical significant. CA-199, carbohydrate antigen 199; TNM, tumor-nodes-metastases; Ref., reference; HR, hazard ratio; CI, confidential interval; NA, not adopted; NS, not significant; TTR, time to relapse; OS, overall survival.